Castle Biosciences (CSTL) Receivables (2018 - 2026)

Castle Biosciences has reported Receivables for 9 years, with the latest figure at $48.3 million in Q2 2026.

• Quarterly Receivables fell 7.59% year-over-year to $48.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $48.3 million (down 7.59% YoY) and the FY2025 annual result came in at $43.4 million, down 15.3% from the prior year.
• Receivables improved to $48.3 million in Q2 2026 per CSTL's latest filing, from $42.3 million in the prior quarter.
• Over five years, Receivables peaked at $56.4 million in Q1 2025 and troughed at $19.9 million in Q1 2022.
• A 5-year average of $39.2 million and a median of $42.5 million in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2023 and 2026: Receivables soared 63.15% in 2023, then slipped 25.0% in 2026.
• Over 5 years, Receivables stood at $23.5 million in 2022, then soared by 63.15% to $38.3 million in 2023, then soared by 33.72% to $51.2 million in 2024, then declined by 15.3% to $43.4 million in 2025, then grew by 11.43% to $48.3 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $48.3 million, $42.3 million, and $43.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.